Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatic Resection After HAIC + Adebrelimab + Rivoceranib in Resectable HCC
NCT07684040Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Aug 2026
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, Rivoceranib in hepatocellular carcinoma (HCC), sponsored by The Affiliated Hospital of Guangdong Medical University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07684040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07684040.